When you get really big, and this would be a scale economy, are there contractual relationships with formularies that entrench you and make it so that even if someone else comes out with something similar to treat any given condition, and your patent isn't defending you because it's a different molecule, well, sorry, you've locked up a distribution channel with the PBM and getting on the formulary in such a way that like, good luck to anyone else
Glutarylation on lysine residues (K glu ) was first observed on mitochondrial proteins, where glutarylation of carbamoyl phosphate synthetase 1 reduced enzyme activity and altered ammonia clearance 5
The concentration of ethanol solution varied with the modeling time, increasing from 520% (mice were offered with 5% ethanol (v/v) for 1 week, then 10% ethanol (v/v) for the next 2 weeks, and 15% ethanol (v/v) for the next 3 weeks, finally animals had access to 20% ethanol (v/v) for last 4 weeks)
doi: 10.4049/jimmunol.2100102 98 ShaoXSunSZhouYWangHYuYHuTet al